Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry
Open Access
- 8 March 2024
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 19 (1) , 1-11
Abstract
Background: Hypophosphatasia (HPP) is a rare inherited disease caused by deficient activity of tissue-nonspecific alkaline phosphatase. Many adults with HPP have a high burden of disease, experiencing chronic pain, fatigue, limited mobility, and dental issues, contributing to decreased health-related quality of life (HRQoL). HPP may be treated with the enzyme replacement therapy asfotase alfa though real-world data in adults are limited. This analysis was conducted to assess the clinical effectiveness of asfotase alfa among adults in the Global HPP Registry. Methods: The Global HPP Registry is an observational, prospective, multinational study. Adults ≥ 18 years of age were included in this analysis if they had serum alkaline phosphatase (ALP) activity below the age- and sex-adjusted reference ranges, and/or ALPL variant(s), and received asfotase alfa for ≥ 6 months. Mobility was assessed with the 6-Minute Walk Test (6MWT), and patient-reported outcomes tools were used to assess pain (Brief Pain Inventory-Short Form), quality of life (36-item Short Form Health Survey, version 2 [SF-36v2]), and disability (Health Assessment Questionnaire-Disability Index) at multiple time points from baseline through Month 36. Data were collected as per usual standard of care; patients may not have contributed data at all time points. Results: A total of 190 patients met the inclusion criteria. For patients with ≥ 1 follow-up measurement, the mean distance achieved on 6MWT increased from 404 m (range 60–632 m) at baseline (n = 31) to 484 m at Month 12 (range 240–739 m; n = 18) and remained above baseline through Month 36 (n = 7). Improvements in mean self-reported pain severity scores ranged from − 0.72 (95% CI: − 1.23, − 0.21; n = 38) to − 1.13 (95% CI: − 1.76, − 0.51; n = 26) and were observed at all time points. Improvements in the Physical Component Summary score of SF-36v2 were achieved by Month 6 and sustained throughout follow-up. There was a trend toward improvement in the Mental Component Summary score of SF-36v2 at most time points, with considerable fluctuations from Months 12 (n = 28) through 36 (n = 21). The most frequent adverse events were injection site reactions. Conclusions: Adults with HPP who received asfotase alfa for ≥ 6 months experienced improvements in mobility, physical function, and HRQoL, which were maintained over 3 years of follow-up. Registration: NCT02306720; EUPAS13514.Keywords
Funding Information
- Alexion Pharmaceuticals
This publication has 21 references indexed in Scilit:
- Bone turnover and mineral metabolism in adult patients with hypophosphatasia treated with asfotase alfaOsteoporosis International, 2021
- Measuring Outcomes Over Time in Distal Radius Fractures: A Comparison of Generic, Upper Extremity-Specific and Wrist-Specific Outcome MeasuresJournal of Hand Surgery Global Online, 2020
- Burden of Illness in Adults With Hypophosphatasia: Data From the Global Hypophosphatasia Patient RegistryJournal of Bone and Mineral Research, 2020
- Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasiaBone, 2019
- Reliability and Validity of the 6‐Minute Walk Test in HypophosphatasiaJBMR Plus, 2018
- Hypophosphatasia: An overview For 2017Bone, 2017
- Burden of disease in adult patients with hypophosphatasia: Results from two patient-reported surveysMetabolism, 2016
- Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremitiesArthritis & Rheumatism, 2001
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- EXCRETION OF INORGANIC PYROPHOSPHATE IN HYPOPHOSPHATASIAThe Lancet, 1965